A5082364647- Peptidase Inhibition and Analysis
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Cancer Mechanisms and Therapy
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- RNA Interference and Gene Delivery
- Nanoplatforms for cancer theranostics
- Cancer therapeutics and mechanisms
- Nanoparticle-Based Drug Delivery
- Angiogenesis and VEGF in Cancer
- Cancer Research and Treatments
Jiangsu Hengrui Medicine (China)
2022-2025
Hubei Polytechnic University
2024
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor, characterized by high heterogeneity, strong invasiveness, poor prognosis, and a low survival rate. A broad range of nanoparticles have been recently developed as drug delivery systems for GBM therapy owing to their inherent size effect ability cross blood-brain barrier (BBB). Lipid-based (LBNPs), such liposomes, solid lipid NPs (SLNs), nano-structured carriers (NLCs), emerged promising system treatment because...
Background: For non-small-cell lung cancer (NSCLC) patients who progressed after first-line chemotherapy, immunotherapy targeting programmed cell death (ligand) 1 has shown promising activity. However, the activity is relatively limited in harboring epidermal growth factor receptor (EGFR) mutations. Objectives: This study aimed to evaluate efficacy and safety of camrelizumab plus famitinib previously treated with locally advanced metastatic NSCLC. Design: A single-center, single-arm, phase...
Background: Immunotherapy (PD-1/PD-L1 antibody) combined with platinum-based chemotherapy has been established as the standard first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). Our previous study showed that nab-paclitaxel had promising efficacy later line setting in ES-SCLC. This phase 2 trial aimed to evaluate and safety of camrelizumab (PD-1 plus carboplatin ES-SCLC.Methods: Inclusion criteria included aged 18-75 years, histologically or cytologically confirmed...
6061 Background: Concurrent chemoradiotherapy (CCRT) is currently considered to be the standard treatment for locoregionally advanced nasopharyngeal carcinoma (LA-NPC), accompanied with non-neglectable toxicity and unsatisfactory compliance. Therefore, it highly warranted explore an alternative regimen LA-NPC. This trial aimed assess investigate efficacy safety of recombinant human endostatin ( Rh-endostatin) intensity-modulated radiotherapy (IMRT) low-risk Methods: Patients LA-NPC were...
8564 Background: Impower133 and CASPIAN studies showed that PD-L1 antibody combined with first-line chemotherapy could prolong the overall survival. Our previous study nab-paclitaxel had a promising efficacy as later line setting in ES-SCLC. This phase II trial aimed to evaluate safety of camrelizumab plus carboplatin front-line Methods: Key inclusion factors were18-75 years old, histologically or cytologically confirmed ES-SCLC, ECOG performance status 0-1, no systematic treatment. Patients...